Gilead’s Voluntary Licensing Agreements for Remdesivir with 5 generic companies
Posted on13 May 2020
Tagsdrug licensing, gilead, global pharma licensing deal, licensing deal in pharma, mylan licensing deal, nonexclusive, Remdesivir
Comments0
Gilead has signed non-exclusive voluntary licensing agreements with five generic pharmaceutical manufacturers based in India and Pakistan to further expand supply of remdesivir.... Read More
Gilead Sciences, Second Genome ink collaboration strategic deal in biomarker and inflammatory bowel disease drug discovery
Gilead Sciences, Inc and Second Genome, a leader in microbiome science, announced that the companies have entered into a four-year strategic collaboration... Read More
Case Study: Compassionate use of remdesivir of Gilead for COVID-19
Posted on06 Apr 2020
Comments0
During an extraordinary virtual meeting held on April 2, 2020, EMA’s human medicines committee (CHMP) gave recommendations on how the investigational antiviral... Read More
Gilead’s Epclusa receives US FDA approval to treat chronic hepatitis C infection for children ages 6 & older
US FDA has approved a supplemental New Drug Application (sNDA) for Epclusa (sofosbuvir 400mg/velpatasvir 100mg; sofosbuvir 200mg/velpatasvir 50 mg) for the treatment... Read More
Gilead introduces Asia Pacific Rainbow Grants program
Gilead Sciences announced the launch of the 2019 Gilead Asia Pacific Rainbow Grants programme to support community-led programs for people living with... Read More
Pharma M&A Case Study: Gilead Sciences’s acquisition of Kite Pharma
Posted on03 Sep 2017
Comments0
Gilead Sciences is in process of acquiring Kite Pharma, one of the most advanced players in the CAR-T therapy market. In this... Read More
USFDA approved Epclusa for treatment of chronic Hepatitis C virus infection
Brand Name: Epclusa Type: Fixed Dose Combination Molecule: Velpatasvir + sofosbuvir Manufactured By: Gilead Sciences, Inc Marketed By: Gilead Sciences, Inc Velpatasvir/sofosbuvir... Read More
Gilead’s single tablet regimen Odefsey got EU marketing authorization for HIV treatment
The European Commission has granted marketing authorization for Gilead Sciences’ once-daily single tablet regimen (STR) Odefsey (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide... Read More
Novozyme Ranked 1 in among top 20 global biotech employers for 2015
Posted on03 Nov 2015
TagsAbbott, AbbVie, Alexion Pharmaceuticals, Bayer, Biocon, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Genentech, gilead, Merck KGaA, Moderna Therapeutics, Monsanto Company, Novozymes, Regeneron Pharmaceuticals Novo Nordisk, Roche—excluding Genentech, Top 10 Biotech company globally, vertex pharmaceuticals
Comments0
Novozymes has earned 1st rank globally on top biotechnology employers in the world as ranked by American Association for the Advancement of Science (AAAS).... Read More
After Zydus Candila & Natco, Now DRL launching Gilead’s Sofosbuvir in India
Posted on24 Mar 2015
Comments0
Dr Reddy’s Laboratories entered into an agreement with Hetero to distribute and market generic version of US-firm Gilead Sciences’ Hepatitis C drug... Read More